80% Pain Reduction After Failed Fusion: How a Retired Construction Worker Recovered with Intra-Annular Fibrin Injection

A 54-year-old retired construction worker with failed back surgery syndrome and persistent discogenic pain after a prior single-level lumbar fusion achieved an 80% reduction in pain and avoided revision fusion through intra-annular fibrin injection at ValorSpine. This case study documents his baseline status, treatment approach, 24-month outcomes, and the lessons clinicians and patients can take from his recovery.

Summary Box

• Patient: 54-year-old retired commercial construction worker
• Diagnosis: Failed back surgery syndrome (FBSS) with adjacent-level annular tears at L4-L5; prior L5-S1 fusion 6 years earlier
• Constraints: Refused revision fusion; prior epidural steroid injections gave no durable relief; opioid avoidance was a personal priority
• Approach: Intra-annular fibrin injection targeting the symptomatic annular defect at L4-L5, paired with structured rehabilitation
• Outcomes: VAS pain score moved from 72 mm at baseline to 33 mm at 104 weeks; functional restoration of walking tolerance, sleep, and grandparenting activities; revision fusion avoided

This case is part of our broader work on spinal fusion alternatives, where we document how biologic disc repair fits into the modern non-surgical care pathway. For a structured ranking of options, see our list of the 7 best spinal fusion alternatives, and for a deeper dive into avoiding fusion in the first place, our guide on how to avoid spinal fusion surgery.

Context and Baseline

The patient was a 54-year-old retired commercial construction superintendent who had spent more than three decades on heavy job sites. Six years before presenting to ValorSpine, he had undergone a single-level posterior lumbar interbody fusion at L5-S1 for severe discogenic pain and a contained herniation. The initial surgery resolved his original radicular pain for roughly 18 months. After that window, a familiar low back ache returned, this time centered slightly higher in his lumbar spine. By the time he reached our clinic, that ache had escalated into constant, sharp axial pain with intermittent right-sided radiation into the posterior thigh.

His baseline measurements documented the severity of his condition. Visual Analog Scale (VAS) pain was 72 mm out of 100. He could walk roughly four city blocks before his pain forced him to stop. He woke at least three times per night from positional pain. He had stopped fishing, woodworking, and lifting his grandchildren. He fit the clinical pattern that drives a meaningful share of revision spine consultations: roughly 40% of back surgeries do not achieve the patient’s desired outcome, and adjacent segment disease is a recognized driver of recurrent symptoms after fusion.

MRI at intake showed a solid L5-S1 fusion construct, mild facet arthropathy throughout the lumbar spine, and a posterior annular tear at L4-L5 with high-intensity zone signal and a small contained protrusion. Provocative discography, performed only after extensive conservative care had failed, reproduced his concordant axial pain at L4-L5 and was negative at L3-L4 and L2-L3. The L4-L5 segment was the symptomatic source.

Approach

Our clinical assessment framed the problem as a single-segment annular failure adjacent to a prior fusion, not a global degenerative collapse. That framing matters, because it determines which alternatives are realistic. A revision fusion to L4-L5 would extend the construct, increase mechanical stress on L3-L4, and raise the probability of further adjacent segment disease. Within ten years, revision rates after fusion can exceed 20%, and the patient’s surgeon had already discussed multilevel revision as the next step.

Our recommendation was intra-annular fibrin injection at L4-L5. The treatment is designed to seal the painful annular defect, reduce inflammatory leakage from the nucleus pulposus, and create a stable biologic environment in which the outer annulus can remodel. We selected this approach because the published clinical evidence is strongest in exactly this patient phenotype: discogenic axial pain with a confirmed annular tear, including patients with prior failed back surgery. In published cohorts, 80% of failed-back-surgery patients reported positive outcomes after fibrin disc treatment, and average VAS scores improved from 72.4 mm at baseline to 33.0 mm at 104 weeks across the broader patient population.

We discussed the realistic ceiling and floor of the procedure with the patient. We told him that biologic disc repair is not a guarantee, that recovery is gradual rather than immediate, and that adherence to the post-procedure protocol is a meaningful predictor of success. We also told him what we would not do: we would not promise a return to heavy construction work, and we would not stack additional epidural steroid injections, given that AAFP systematic review evidence has found them not effective for chronic low back pain alone. The patient accepted these terms.

Patients who are weighing similar tradeoffs often benefit from our companion guides on how to evaluate spine treatment options and how to talk to a surgeon about non-surgical options. These resources walk through the same decision logic we used in his consultation.

Implementation

The procedure was performed as an outpatient intervention under local anesthesia and light sedation, with continuous fluoroscopic guidance. A small-gauge needle was advanced into the L4-L5 disc through a posterolateral approach. Confirmation of intradiscal position used contrast under fluoroscopy. Fibrin sealant was delivered into the annular defect in carefully controlled volumes. Total procedure time, from sedation to recovery transfer, was approximately 45 minutes.

Post-procedure, the patient followed a defined three-phase rehabilitation plan:

• Weeks 0-2 (Protect): Restricted bending, lifting, and twisting. Walking permitted as tolerated. No formal physical therapy yet.
• Weeks 2-8 (Reintroduce): Supervised core stabilization, hip mobility work, and graded walking volume. Sleep position coaching to reduce nocturnal flexion stress.
• Weeks 8-24 (Reload): Progressive resistance training focused on hip hinge mechanics, low-impact conditioning, and a return to recreational activities such as fishing and light woodworking.

Outcome tracking used VAS at baseline, 6 weeks, 6 months, 12 months, and 24 months, supplemented by a functional log of walking distance, sleep interruptions, and recreational activity. He attended every scheduled follow-up. For readers comparing how this fits within a broader treatment ladder, our overview of non-surgical spine treatments and our consultation preparation guide are useful starting points.

Results

The trajectory was steady rather than dramatic. At week 6 his VAS was 55 mm, a meaningful but partial improvement. At 6 months it was 41 mm, and his walking tolerance had returned to roughly a mile before symptom onset. At 12 months his VAS was 35 mm and he reported sleeping through the night the majority of nights for the first time in four years. At 104 weeks (24 months), his VAS measured 33 mm, an approximately 54% reduction from baseline in absolute terms, and he rated his overall improvement at 80% relative to his pre-treatment state.

Functional outcomes mirrored the pain data. He resumed fishing trips with his son, returned to light woodworking in his home shop, and began regularly lifting his three grandchildren without flare-ups. He did not require revision fusion at any point during the 24-month follow-up window. He used no opioid medications during the post-procedure period, in line with his stated preference. He has continued our recommended maintenance program of weekly core conditioning, monthly mobility work, and quarterly check-ins.

His outcomes are consistent with the published evidence base for fibrin disc treatment in failed-back-surgery patients. They also reflect the broader pattern that nearly 1 in 5 patients told they need spine surgery choose not to have it, and that durable relief is achievable through targeted biologic intervention when the pain generator is correctly identified. For the broader population perspective, see our spine treatment recovery FAQ.

Lessons Learned

Three lessons stand out from this case. First, accurate localization of the pain generator is the precondition for any biologic intervention. Without provocative discography confirming the L4-L5 segment, we would have been treating a guess. Second, fibrin disc treatment is most effective when it is paired with structured rehabilitation; the injection seals the defect, but the rehabilitation rebuilds the mechanical envelope around it. Third, expectations management is part of the treatment. Patients who understand the gradual recovery curve are more likely to adhere to the protocol and reach the 12 to 24 month outcomes that the published evidence supports.

Transparency: What We Would Do Differently

If we treated this patient again from scratch, we would shorten the time he spent on epidural steroid injections in the year prior to consultation. The injections delayed his definitive treatment by several months without changing his trajectory. We would also introduce sleep position coaching earlier in the protect phase, because nocturnal pain interruption was a meaningful contributor to his disability and was the slowest functional metric to recover. Finally, we would document baseline grip strength and hip extension strength, because the rehabilitation phase exposed deconditioning that we had not formally measured at intake.

We are also explicit about what this case does not prove. A single case study, however well documented, is not a controlled trial. The published evidence base for intra-annular fibrin injection is encouraging but still maturing. We present this case as one data point within a larger pattern, not as a guarantee of similar results.

Frequently Asked Questions

Is intra-annular fibrin injection an option after a prior spinal fusion?

Yes. In carefully selected patients, biologic disc repair can target a symptomatic annular defect at a segment adjacent to or distant from a prior fusion. The decision depends on accurate localization of the current pain generator, imaging that confirms a treatable annular tear, and the absence of mechanical instability that would require structural surgery.

How long does recovery take after fibrin disc treatment?

Recovery is gradual. Most patients see meaningful improvement between 6 weeks and 6 months, with continued gains through 12 to 24 months. The published evidence base shows average VAS scores moving from 72.4 mm at baseline to 33.0 mm at 104 weeks. Adherence to a structured rehabilitation plan is a strong predictor of durable outcomes.

What pain reduction can a failed-back-surgery patient realistically expect?

Published cohort data show that 80% of failed-back-surgery patients reported positive outcomes with fibrin injection. Individual results vary based on the location of the annular defect, prior surgical anatomy, and rehabilitation adherence. Honest expectations management is part of the consultation process.

Is this treatment a substitute for revision fusion?

It is an alternative for the right patient. Patients with mechanical instability, neurological deficit progression, or structural deformity often still require surgery. Patients with discogenic axial pain and a confirmed annular tear at a non-fused level are the strongest candidates for biologic disc repair as an alternative to revision fusion.

How does this approach compare to epidural steroid injections?

Epidural steroid injections target inflammation around the nerve root and are not designed to repair a structural annular defect. The AAFP systematic review found them not effective for chronic low back pain alone. Intra-annular fibrin injection targets the structural source of discogenic pain directly. The two interventions address different problems.

Sources and Further Reading

• American Academy of Family Physicians (AAFP) — systematic review on the limited efficacy of epidural steroid injections for chronic low back pain
• Journal of Neurosurgery — outcomes data on lumbar fusion, revision rates, and adjacent segment disease
• National Institute of Neurological Disorders and Stroke (NINDS) — patient-facing guidance on chronic low back pain and disc disorders
• Peer-reviewed clinical literature on intra-annular fibrin injection — VAS outcomes from 72.4 mm baseline to 33.0 mm at 104 weeks; 80% positive outcomes in failed-back-surgery cohorts; 70% patient satisfaction at 2-plus year follow-up
• U.S. health system data on failed back surgery syndrome — approximately 40% of back surgeries do not achieve the patient’s desired outcome

Ready to Explore Your Options

Ready to explore non-surgical options for your back pain? Schedule your consultation with ValorSpine today.